Clinical Trial Update: QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial update for QL1604 monotherapy in dMMR or MSI-H advanced solid tumors (advanced malignant tumor).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Tumor

Drugs mentioned

• QL1604

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Advanced Malignant Tumor | Phase 2 | Status: UNKNOWN